The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial.
E. B. Garon
Consultant or Advisory Role - Oxigene (U)
Research Funding - Oxigene
F. F. Kabbinavar
No relevant relationships to disclose
J. A. Neidhart
Research Funding - Oxigene
J. D. Neidhart
Research Funding - Oxigene
N. Y. Gabrail
No relevant relationships to disclose
M. R. Oliveira
Consultant or Advisory Role - Oxigene
S. Lu
Employment or Leadership Position - Oxigene
J. Balkissoon
Employment or Leadership Position - Oxigene
Stock Ownership - Oxigene